Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia

被引:14
作者
Seiter, K
Feldman, EJ
Halicka, HD
Deptala, A
Traganos, F
Burke, HB
Hoang, A
Goff, H
Pozzuoli, M
Kancherla, R
Darzynkiewicz, Z
Ahmed, T
机构
[1] New York Med Coll, Zalmen A Arlin Canc Inst, Valhalla, NY 10595 USA
[2] New York Med Coll, Dept Med, Valhalla, NY 10595 USA
[3] New York Med Coll, Brander Canc Res Inst, Valhalla, NY 10595 USA
关键词
acute myelogenous leukaemia; all-trans retinoic acid; chemotherapy; bcl-2; apoptosis;
D O I
10.1046/j.1365-2141.2000.01804.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
All-trans retinoic acid (ATRA) is synergistic with chemotherapy in leukaemia cell lines. We treated 53 patients with newly diagnosed acute myelogenous leukaemia (AML) with high-dose cytarabine-based chemotherapy followed by ATRA. Peripheral blood and bone marrow samples were obtained to study the effect of in vitro exposure to ATRA and to measure apoptosis and bcl-2. The response rate was 72% for patients under age 60 years and 46% for patients aged 60 years or above. There was no difference in the percentage of responding patients, time to recurrence or overall survival for patients receiving chemotherapy with ATRA vs. historical controls receiving chemotherapy without ATRA. After in vitro exposure of day 3 bone marrow samples to ATRA, there was an increase in apoptotic cells in 25% of patient samples compared with samples not exposed to ATRA. Later date of peak apoptosis in peripheral blood and higher percentage of apoptotic cells in bone marrow on day 3 of treatment were associated with lack of clinical response to treatment. increased bcl-2 in patient samples was associated with shorter time to recurrence and poor cytogenetic risk. The addition of ATRA to chemotherapy did not improve patient outcome. However evidence of in vitro response to ATRA in 25% of patients suggests that retinoid pathways should be studied further in patients with AML.
引用
收藏
页码:40 / 47
页数:8
相关论文
共 21 条
[1]  
BHATIA U, 1995, CELL GROWTH DIFFER, V6, P937
[2]   Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression [J].
Bradbury, DA ;
Aldington, S ;
Zhu, YM ;
Russell, NH .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 94 (04) :671-675
[3]  
Cambier N, 1996, LEUKEMIA, V10, P1164
[4]  
CAMPBELL P, 1993, PHYS WORLD, V6, P7
[5]   Randomized phase II study of fludarabine plus cytosine arabinoside plus idarubicin ± all-trans retinoic acid ± granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome [J].
Estey, EH ;
Thall, PF ;
Pierce, S ;
Cortes, J ;
Beran, M ;
Kantarjian, H ;
Keating, MJ ;
Andreeff, M ;
Freireich, E .
BLOOD, 1999, 93 (08) :2478-2484
[6]   A randomized trial of high- vs standard-dose mitoxantrone with cytarabine in elderly patients with acute myeloid leukemia [J].
Feldman, EJ ;
Seiter, K ;
Damon, L ;
Linker, C ;
Rugo, H ;
Ries, C ;
Case, DC ;
Beer, M ;
Ahmed, T .
LEUKEMIA, 1997, 11 (04) :485-489
[7]  
FELDMAN EJ, 1999, IN PRESS LEUKEMIA LY
[8]  
GOLD EJ, 1983, CANCER TREAT REP, V67, P981
[9]  
GREENBERG BR, 1985, CANCER TREAT REP, V69, P1369
[10]   USE OF DIFFERENTIATION-INDUCING AGENTS IN THE MYELODYSPLASTIC SYNDROME AND ACUTE NON-LYMPHOCYTIC LEUKEMIA [J].
HOFFMAN, SJ ;
ROBINSON, WA .
AMERICAN JOURNAL OF HEMATOLOGY, 1988, 28 (02) :124-127